Price transparency of cancer medicines: a crucial step towards informed pricing negotiations in the European region
Frontiers in Pharmacology · 09.03.2026 · 17
DOI: 10.3389/fphar.2026.1736741 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 09.03.2026. Verfasst von Julie Vancoppenolle und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Amsterdam, Amsterdam, Netherlands. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The increasing cost of cancer medicines is a growing concern for hospitals in the European region, leading to cost reduction strategies, such as price negotiations. The objective of this study is to compare actual prices and discounts of cancer medicines at hospital level across the European region.
Methods
To report prices and discounts without compromising the hospitals’ anonymity, an anonymization pathway was developed. Pricing data of 15 cancer medicines in 2022 was collected through structured interviews with hospital staff and reference prices were derived from the IQVIA-MIDAS dataset. Descriptive analyses were used to demonstrate product and reference prices. Discounts were aggregated across countries and product types. Furthermore, the accuracy of the participants’ perceptions of their prices compared to others within their country was assessed.
Results
23 hospitals from nine countries participated. To comply with the anonymization pathway, three countries were presented in general terms. The highest prices at hospital level were observed in France, followed by Serbia, Germany, Hungary and the Netherlands. Two Southern and one Northern European country had the lowest prices. When comparing them with their reference prices, Serbia reports the lowest discounts (−7%) and the Southern European countries the highest discounts (−38%). In addition, at least half of the hospitals had incorrect perceptions of their prices relative to others within their country, with some up to 22% higher than average.
Discussion
Our study is one of few providing discounts and actual prices for 15 cancer medicines, revealing large price variations between and within countries. Additionally, reference prices often fail to provide an accurate indication of the actual price and hospitals have often misguided perceptions on their negotiation performance. Transparent, standardized reporting of prices and coordinated collaborations are essential to strengthen the bargaining power of hospitals and foster informed price negotiations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Amsterdam, Amsterdam, Netherlands.
- Health Technology and Services Research Department, Technical Medical Centre, University of Twente, Enschede, Netherlands.
- Oncological Pharmacy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
- Department of Clinical Research, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark.
- The Capital Region Pharmacy, Herlev, Denmark.
- Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
Zitieren
APA
Vancoppenolle, J., Franzen, N., Andrianò, C., Houlind, M. B., Ćetković, Z., Dane, A., Degrassat-Théas, A., Eldering-Heldens, A. M. P., Hug, M. J., Knoth, H., Ladisa, V., Vajda, P., Warnke, U., Retèl, V., & van Harten, W. H. (2026). Price transparency of cancer medicines: a crucial step towards informed pricing negotiations in the European region. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1736741
Vancouver
Vancoppenolle J, Franzen N, Andrianò C, Houlind MB, Ćetković Z, Dane A, et al. Price transparency of cancer medicines: a crucial step towards informed pricing negotiations in the European region. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1736741
BibTeX
@article{Vancoppenolle2026,
author = {Vancoppenolle, Julie and Franzen, Nora and Andrianò, Cristina and Houlind, Morten Baltzer and Ćetković, Zora and Dane, Aniek and Degrassat-Théas, Albane and Eldering-Heldens, Anne M P and Hug, Martin J and Knoth, Holger and Ladisa, Vito and Vajda, Péter and Warnke, Ulrich and Retèl, Valesca and van Harten, Wim H},
title = {Price transparency of cancer medicines: a crucial step towards informed pricing negotiations in the European region},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1736741}
}
EUVIMED